Skip to main content
  • Disease Background
  • Symptoms
  • Diagnosis
  • Sign Up
    For Updates
Not an actual patient
Solve the case of his lifetime

Identifying the link can lead to a crucial diagnosis

Hereditary ATTR amyloidosis is a rapidly progressive disease that may eventually rob patients of function—and their lives.1-3

Find out how you can help accelerate time to diagnosis.

Red-flag symptoms of hATTR amyloidosis

Learn about how to recognize the signs in your patients

What is hATTR amyloidosis?

Facts about the disease

Sign up to receive updates

Stay up-to-date on news about hATTR amyloidosis

References:

  1. Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50-57.
  2. Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675-682.
  3. Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-540.
Alnylam Pharmaceuticals

©2019 Developed and produced by Alnylam Pharmaceuticals, Inc. All rights reserved.
The information on this site is intended for UK and Ireland healthcare professionals.
TTR02-UKI-00052. Date of Preparation: 12.2019

  • Legal
  • Privacy Policy
  • Contact
  • Sitemap
 
 
Home

 

You are now leaving hattramyloidosis.co.uk

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from the site’s standards you are leaving.

Third Party Sites

Alnylam assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Alnylam or this website.

Thank you for visiting our site.

Cancel
Continue

 

The information on this site is intended for UK and Ireland healthcare professionals and is not intended for the general public.

I am a healthcare professional.
I am not a healthcare professional.

Sign up to receive updates about hereditary ATTR amyloidosis from Alnylam

*Required Fields

By clicking submit, you certify that you are a healthcare professional.

Thank you

Your submission has been received.

Return to site

You are now leaving hATTR amyloidosis.com

Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

OK
CANCEL